Vacuum tumescence devices: the role of papaverine in the selection of patients.
We conducted a prospective study to determine the positive predictive value of papaverine testing to select patients in whom a vacuum constriction device would be a successful alternative to operative management of impotence. A total of 30 men presenting to an impotence clinic was evaluated with a series of papaverine dosages up to 60 mg. These patients then received a physician-administered trial of a vacuum constriction device, followed by 3 months of home use and a repeat objective evaluation. Initial responses to the device were poor, with 46% of the patients (14) achieving a rigid erection. However, after 3 months of home use 83% of the patients (25) achieved a rigid erection. The positive predictive value of a good response to the papaverine trial was 94%.
Broderick
G A
GA
Department of Urology, University of California, School of Medicine, San Francisco 94143-0738.
Allen
G
G
McClure
R D
RD
D004867:Equipment Design; D007172:Erectile Dysfunction / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010208:Papaverine; D010410:Penile Erection / Q000187:drug effects*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D013997:Time Factors; D014618:Vacuum
D010208:Papaverine